Rationale in the Use of Adjuvant Chemotherapy in pT3N0M0 Gastric Cancer Resected Patients. Comment on Chen et al. Prognostic Factors and the Role of Adjuvant Chemotherapy in Pathological Node-Negative T3 Gastric Cancer. J. Pers. Med. 2023, 13, 553

Abstract

I read with great interest the well-written and well-made study by Yi-Fu Chen et al. recently published in the “Journal of Personalized Medicine” [...]

Reply to Graziosi et al. Rationale in the Use of Adjuvant Chemotherapy in pT3N0M0 Gastric Cancer Resected Patients. Comment on “Chen et al. Prognostic Factors and the Role of Adjuvant Chemotherapy in Pathological Node-Negative T3 Gastric Cancer. J. Pers. Med. 2023, 13, 553”

“…We appreciate the authors very much for their interest in our article “Prognostic factors and the role of adjuvant chemotherapy in pathological node-negative T3 gastric cancer” [ 1 ]. We also greatly agree with their comments that to identify clinical and molecular predictive and prognostic factors in patients at high risk of recurrence who could benefit from the adjuvant chemotherapy is important [ 2 ]. The patients enrolled during 1994 and 2020 in our study did not receive neoadjuvant chemotherapy [ 1 ].…”